<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>golimumab</strong></td></tr><tr><th>Accession Number</th><td><strong>DB06674</strong></td></tr><tr><th>Type</th><td>biotech</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Golimumab is a human IgG1&#1179; monoclonal antibody derived from immunizing genetically engineered mice with human TNF&#945;. Golimumab binds and inhibits soluble and transmembrane human TNF&#945;. Increased TNF&#945; is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi&#174;. The <span class="caps">FDA</span> label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.</p></td></tr><tr><th>Protein structure</th><td><img alt="No structure small" src="/assets/no_structure_small-e8790a148b09ecc5ad9f5b4926a538e7.png"></td></tr><tr><th>Protein chemical formula</th><td>C<sub>6530</sub>H<sub>10068</sub>N<sub>1752</sub>O<sub>2026</sub>S<sub>44</sub> </td></tr><tr><th>Protein average weight</th><td>146943.1937 daltons</td></tr><tr><th>Sequences</th><td></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Simponi</td><td>Centocor Ortho Biotec</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antipsoriatic-agents">Antipsoriatic Agents</a></li>
<li><a href="/mesh/monoclonal-antibodies">Monoclonal antibodies</a></li>
<li><a href="/mesh/tnf-inhibitor">TNF inhibitor</a></li></ul></td></tr><tr><th>CAS number</th><td>476181-74-5</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Peptides</td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.

</td></tr><tr><th>Pharmacodynamics</th><td>Golimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNF&#945;). In areas such as the joints and blood, increased TNF&#945; is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.

 </td></tr><tr><th>Mechanism of action</th><td>As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNF&#945;. Inhibition of TNF&#945; prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
  

  

 </td></tr><tr><th>Absorption</th><td>After subcutaneous administration, golimumab can achieve 
maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 &#177; 1.4 &#956;g/mL. </td></tr><tr><th>Volume of distribution</th><td><p>After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.</p></td></tr><tr><th>Protein binding</th><td>Plasma protein binding was not quantified.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>The metabolism of golimumab has yet to be determined.</p></td></tr><tr><th>Route of elimination</th><td>The route of elimination for golimumab has yet to be determined.</td></tr><tr><th>Half life</th><td>Golimumab has a long half-life of about 2 weeks.</td></tr><tr><th>Clearance</th><td><p>After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.</p></td></tr><tr><th>Toxicity</th><td>The FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, solution</td><td>Subcutaneous</td><td>100 mg/1 mL</td></tr><tr><td>Injection, solution</td><td>Subcutaneous</td><td>50 mg/0.5 mL</td></tr></tbody></table></td></tr><tr><th>Prices</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Patents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>liquid</td></tr><tr><th>Experimental Properties</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC, Pendley C, Jiao Q, Shankar G, Marciniak SJ, Cohen SB, Rahman MU, Baker D, Mascelli MA, Davis HM, Everitt DE: Pharmacokinetics and safety of golimumab, a fully human anti-<span class="caps">TNF</span>-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol. 2007 Mar;47(3):383-96.</p></span></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li><span class="caps">FDA</span> label.</li>
	<li>Oldfield V, Plosker GL: Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. BioDrugs. 2009;23(2):125-35. doi: 10.2165/00063030-200923020-00005. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19489653">Pubmed</a></li>
	<li>Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Jarnerot G, Rutgeerts P: Subcutaneous Golimumab Maintains Clinical Response in Patients with Moderate-To-Severe Ulcerative Colitis. Gastroenterology. 2013 Jun 13. pii: S0016-5085(13)00886-X. doi: 10.1053/j.gastro.2013.06.010. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23770005">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/simponi-drug.htm" target="_blank">http://www.rxlist.com/simponi-drug.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/mtm/golimumab.html" target="_blank">http://www.drugs.com/mtm/golimumab.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Golimumab" target="_blank">Golimumab <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>L04AB06<ul class="atc-drug-tree"><li><a href="/atc/L#L">L &#8212; ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</a></li><li><a href="/atc/L04#L04">L04 &#8212; IMMUNOSUPPRESSANTS</a></li><li><a href="/atc/L04A#L04A">L04A &#8212; IMMUNOSUPPRESSANTS</a></li><li><a href="/atc/L04AB#L04AB">L04AB &#8212; Tumor necrosis factor alpha (TNF-?) inhibitors</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB06674.pdf?1372011883">show</a>(1.9 MB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB06674.pdf?1372012283">show</a>(567 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01281">Abatacept</a></td><td>Avoid combination with abatacept due to the increased chance of serious infection.

</td></tr><tr><td><a href="/drugs/DB00026">Anakinra</a></td><td>Avoid combination with anakinra due to the increased chance of serious infection.
</td></tr><tr><td><a href="/drugs/DB08879">Belimumab</a></td><td>Avoid combination with belimumab due to the increased chance of belimumab associated side effects.

</td></tr><tr><td><a href="/drugs/DB06168">Canakinumab</a></td><td>Avoid combination with canakinumab due to the increased chance of neutropenia and/or serious infection.</td></tr><tr><td><a href="/drugs/DB08904">Certolizumab pegol</a></td><td>Avoid combination due to the potential increased immunosuppression of Certolizumab Pegol.</td></tr><tr><td><a href="/drugs/DB00065">Infliximab</a></td><td>Avoid combination with infliximab due to the potential increased immunosuppression of infliximab.

</td></tr><tr><td><a href="/drugs/DB00108">Natalizumab</a></td><td>Avoid combination due to the increased chance of infection.

</td></tr><tr><td><a href="/drugs/DB00337">Pimecrolimus</a></td><td>Avoid combination due to enhancement of side effects from immunosuppressants.
</td></tr><tr><td><a href="/drugs/DB06372">Rilonacept</a></td><td>results in increased immunosuppressive effects; increases the risk of infection. </td></tr><tr><td><a href="/drugs/DB06372">Rilonacept</a></td><td>Avoid combination due to the enhancement of rilonacept associated side effects.
</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Avoid combination due to the enhancement of side effects from immunosuppressants.

</td></tr><tr><td><a href="/drugs/DB06273">Tocilizumab</a></td><td>Avoid combination due to the enhanced immunosuppression by TNF blockers.
</td></tr><tr><td><a href="/drugs/DB08895">Tofacitinib</a></td><td>Golimumab, and other anti-TNF immunosuppressants, when used in combination with tofacitinib, may increase the serum concentration of tofacitinib, and increase tofacitinib associated side effects and immunosuppresion. It is recommended to avoid concurrent therapy.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Since golimumab is administered by subcutaneous injection, there are no food effects.</li></ul></td></tr></tbody></table>